Meningitis B Vaccine’s High Price Poses A Health Care Conundrum For College-Bound
This immunization may mark a shift among some vaccine makers to higher-priced, “niche” preventives that protect against very specific and sometimes rare illnesses.
Health Industry
2,501-2,520 of 4,002 results
-
-
5 Governors Press Congress For Fast Bucks To Secure Obamacare Market In 2018
State leaders tell senators that federal dollars are needed this fall to keep insurers participating in Obamacare next year and prevent big hikes in premiums.
By Julie Rovner and Rachel Bluth -
Shedding New Light On Hospice Care: No Need To Wait For The ‘Brink Of Death’
Hospice care often prompts fear and misunderstanding, but the services provided can lead to less pain and trauma at the end of life.
-
Repeal & Replace Watch
Vital Health Officials You’ve Never Heard Of: Insurance Commissioners In The Hot Seat
The fate of the Affordable Care Act’s individual insurance marketplaces remains in play as state insurance commissioners take a central role in the debate.
-
How Below-The-Radar Mergers Fuel Health Care Monopolies
Most acquisitions by hospitals of physician practices are too small to trigger antitrust attention, study says. But a buying spree of “onesies and twosies” doctor practices has driven competition down and prices up.
By Jay Hancock -
Another Way For Anti-Vaxxers To Skip Shots For Schoolkids: A Doctor’s Note
No longer able to get exemptions for personal beliefs in California, parents opposed to inoculations seem to be obtaining medical exemptions for their children, according to a new study.
-
Rep. Chris Collins’ Australian Stock Bet Looks Bleaker
Innate Immunotherapeutics, the Australian biotech firm whose largest shareholder is Buffalo, N.Y.-area congressman Chris Collins, said it expects to close after its multiple sclerosis drug failed in trials.
By Rachel Bluth -
St. Kitts Launches Probe Of Herpes Vaccine Tests On U.S. Patients
After a Kaiser Health News report on an offshore herpes vaccine trial that skirted FDA regulations, St. Kitts and Nevis officials claim they had no knowledge of the testing. An investigation is underway.
-
Pioneering Cancer Gene Therapy Gets Green Light — And $475,000 Price Tag
The USA's first approved gene therapy — to be used to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment.
By Liz Szabo -
Facebook Live: The Prescription Drug Pricing Pipeline
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
-
Mayo Pain Expert: Holistic Approach Helps Patients Ditch Opioids
Painkillers were never designed to be used over the long term, says the head of the Mayo Clinic’s pain rehabilitation center. Instead, patients should try other approaches, including relaxation therapies. But getting insurers to cover them might take coaxing.
-
Offshore Human Testing Of Herpes Vaccine Stokes Debate Over U.S. Safety Rules
Prominent businessmen and an American university supported offshore testing of an experimental vaccine.
-
What Happens If You’re Forced To Switch Health Plans When You’re Sick?
State lawmakers in California have an answer: legislation that would require your new insurer to keep paying for your current doctors even if they’re not in the network.
-
Repeal & Replace Watch
Podcast: ‘What The Health?’ Back To Health Crunch Come September
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Margot Sanger-Katz of The New York Times discuss the continuing efforts in Congress to “repeal and replace” the Affordable Care Act, upcoming open enrollment for individual insurance and Congress’ long health care to-do list for September.
-
Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
-
Doctors Warm To Single-Payer Health Care
Growing numbers of physicians say they support a single-payer health care system, a 180-degree turn in opinion over a decade.
By Rachel Bluth -
CBO: Killing Cost-Sharing Subsidies Would Hike Silver Plan Premiums And Deficit
The change would not be expected to have much long-term effect on the number of uninsured people. But it could cause a shift in which plans are popular with marketplace customers.
-
Insurers Can Bend Out-Of-Network Rules For Patients Who Need Specific Doctors
Individuals who require very specialized care for their health are advised to make their case when a plan doesn’t cover their doctor.
-
Letters to the Editor
Readers Have Their Say … On Pain And Who Stands To Gain In Drug Market
Kaiser Health News gives readers a chance to respond, react and comment on our stories.
-
Podcast: ‘What The Health?’ No Vacation For Insurers
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Sarah Kliff of Vox.com, and Margot Sanger-Katz of The New York Times discuss the state of the individual health insurance markets in the wake of the failure (for now) of Congress’s efforts to repeal and replace the Affordable Care Act.